PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biotechnology company advancing T cell-engaging bispecific antibodies for solid tumors, reported a second-quarter net loss of $8.8 million as it continues to scale its pipeline of oncology therapies.
The company’s operating loss widened from $2.3 million in the same quarter last year, driven primarily by increased research and development (R&D) spending tied to its expanding clinical portfolio. R&D expenses surged to $7.8 million, up from $1.4 million in Q2 2024, reflecting costs associated with its CTIM-76, CT-95, and CT-202 antibody programs. General and administrative costs rose modestly to $1.9 million, mainly due to personnel growth and compensation adjustments.
Despite the higher expenses, Context closed the quarter with $83.5 million in cash and cash equivalents, down from $94.4 million at year-end but sufficient, according to the company, to fund operations into 2027.
CEO Martin Lehr underscored the company’s focus on pipeline execution, highlighting that initial dose escalation data for CTIM-76 and CT-95 are expected in the first half of 2026. In addition, Context anticipates completing regulatory filings for its Nectin-4 targeting candidate, CT-202, in the second quarter of 2026.
Among its recent developments, Context presented clinical and preclinical data at major scientific meetings, including ASCO and AACR, and appointed Dr. Karen Chagin as Chief Medical Officer. The company also participated in key investor and industry conferences during the quarter.
With three novel bispecific antibody candidates in various stages of development, Context continues to position itself as a key player in advancing T cell-based immunotherapies for hard-to-treat cancers.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.